Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 5
2004 2
2005 6
2006 6
2007 14
2008 7
2009 10
2010 14
2011 22
2012 24
2013 40
2014 42
2015 48
2016 69
2017 73
2018 90
2019 112
2020 134
Text availability
Article attribute
Article type
Publication date

Search Results

647 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for zhang tian
Your search for Shangen Tian retrieved no results
miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma.
Luo M, Wu L, Zhang K, Wang H, Zhang T, Gutierrez L, O'Connell D, Zhang P, Li Y, Gao T, Ren W, Yang Y. Luo M, et al. Among authors: zhang t. Cell Death Differ. 2018 Aug;25(8):1457-1472. doi: 10.1038/s41418-017-0053-8. Epub 2018 Jan 18. Cell Death Differ. 2018. PMID: 29348676 Free PMC article.
Generation of Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De Novo Vascular Network.
Low JH, Li P, Chew EGY, Zhou B, Suzuki K, Zhang T, Lian MM, Liu M, Aizawa E, Rodriguez Esteban C, Yong KSM, Chen Q, Campistol JM, Fang M, Khor CC, Foo JN, Izpisua Belmonte JC, Xia Y. Low JH, et al. Among authors: zhang t. Cell Stem Cell. 2019 Sep 5;25(3):373-387.e9. doi: 10.1016/j.stem.2019.06.009. Epub 2019 Jul 11. Cell Stem Cell. 2019. PMID: 31303547 Free PMC article.
Emerging therapeutic targets for patients with advanced prostate cancer.
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Saad F, et al. Among authors: zhang t. Cancer Treat Rev. 2019 Jun;76:1-9. doi: 10.1016/j.ctrv.2019.03.002. Epub 2019 Mar 19. Cancer Treat Rev. 2019. PMID: 30913454 Review.
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ. Min Y, et al. Among authors: zhang t. Nat Nanotechnol. 2017 Sep;12(9):877-882. doi: 10.1038/nnano.2017.113. Epub 2017 Jun 26. Nat Nanotechnol. 2017. PMID: 28650437 Free PMC article.
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T. Zhu J, et al. Among authors: zhang t. J Immunother Cancer. 2018 Jan 25;6(1):4. doi: 10.1186/s40425-018-0314-1. J Immunother Cancer. 2018. PMID: 29368638 Free PMC article. Review.
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI. Koshkin VS, et al. Among authors: zhang t. J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9. J Immunother Cancer. 2018. PMID: 29378660 Free PMC article.
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ. Tucker MD, et al. Among authors: zhang t. Cancer Med. 2019 Aug;8(10):4644-4655. doi: 10.1002/cam4.2375. Epub 2019 Jul 3. Cancer Med. 2019. PMID: 31270961 Free PMC article.
Voices of biotech.
Amit I, Baker D, Barker R, Berger B, Bertozzi C, Bhatia S, Biffi A, Demichelis F, Doudna J, Dowdy SF, Endy D, Helmstaedter M, Junca H, June C, Kamb S, Khvorova A, Kim DH, Kim JS, Krishnan Y, Lakadamyali M, Lappalainen T, Lewin S, Liao J, Loman N, Lundberg E, Lynd L, Martin C, Mellman I, Miyawaki A, Mummery C, Nelson K, Paz J, Peralta-Yahya P, Picotti P, Polyak K, Prather K, Qin J, Quake S, Regev A, Rogers JA, Shetty R, Sommer M, Stevens M, Stolovitzky G, Takahashi M, Tang F, Teichmann S, Torres-Padilla ME, Tripathi L, Vemula P, Verdine G, Vollmer F, Wang J, Ying JY, Zhang F, Zhang T. Amit I, et al. Among authors: zhang t. Nat Biotechnol. 2016 Mar;34(3):270-5. doi: 10.1038/nbt.3502. Nat Biotechnol. 2016. PMID: 26963549 No abstract available.
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Pabla S, et al. Among authors: zhang t. J Immunother Cancer. 2019 Feb 1;7(1):27. doi: 10.1186/s40425-019-0506-3. J Immunother Cancer. 2019. PMID: 30709424 Free PMC article.
SIRT3 promotes lipophagy and chaperon-mediated autophagy to protect hepatocytes against lipotoxicity.
Zhang T, Liu J, Shen S, Tong Q, Ma X, Lin L. Zhang T, et al. Cell Death Differ. 2020 Jan;27(1):329-344. doi: 10.1038/s41418-019-0356-z. Epub 2019 Jun 3. Cell Death Differ. 2020. PMID: 31160717 Free PMC article.
647 results
Jump to page
Feedback